James Robert Burke
My research focuses on the characterization of cognitive change with age. I am specifically interested in delineating the change between normal and pathologic changes associated with aging and developing therapies to delay decline.
My area of expertise is neurodegenerative diseases and dementia with an emphasis on Alzheimer's disease.
Keywords: Alzheimer's disease.
Education and Training
- Fellow in Neurology, Medicine, Duke University, 1989 - 1991
- Resident in Neurology, Medicine, Duke University, 1986 - 1989
- Intern, Medicine, Staten Island University Hospital, 1985 - 1986
- M.D., State University of New York, Brooklyn, 1985
- Ph.D., University of Tennessee, Knoxville, 1981
Selected Grants and Awards
- An Extension Study of ABBV-8E12 in Early Alzheimer's Disease
- A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)
- A randomized, double-blind, placebo-controlled, two cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease
- Duke Creating ADRD Researchers for the Next Generation - Stimulating Access to Research in Residency Program (CARiNG-StARR)"
- Caregivers' Reactions and Experience: Imaging Dementia-Evidence for Amyloid Scanning-CARE IDEAS
- Alzheimer's Disease, Genes, and Pesticide Use in the Agricultural Health Study
- Pesticides, Olfaction, and Prodromal Neurodegeneration Among US Farmers
- A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease
- Care-partner assisted intervention to improve oral health of individuals with mild dementia
- Impact of Disclosing Amyloid Imaging Results to Cognitively Normal Individuals
- A Blinded Longterm Ext Study to Eval the Safety and Efficacy of Pioglitazone (AD-4833 Sust Release 0.8 mg daily) to Slow the Progress of Cog Decline in Subj Who Have completed the AD4833/TOMM40_301 Study w/ Diag of Mild Cog Impair due to Alz Disease.
- A Phase III Clinical Trial to Study the Efficacy & Safety of MK-8931 (SCH900931) in subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)
- A DB, Randomized, Placebo Controlled, Parallel Group Study to Qualify a Biomarker Algorithm for Risk of Developing MCI due to AD and to Test the S&E of Pioglitazone (AD-4833 SR 0.8 mg QD) Delay Onset of MCI due AD in Cognitively Normal Subjects.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects with Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
- Lifestyle, CVD Risk and Cognitive Impairment
- Caregivers' Reactions and Experience: Imaging Dementia - Evidence for Amyloid Scanning - CARE IDEAS
- Novel Retinal Biomarkers for Early Detection of Alzheimer's Disease
- IPA - John F Ervin
- Metabolic Signatures for Alzheimer's Disease
- Epidemiology of Dementia in Cache County, Utah
- NIH State of the Science Conference on Preventing Alzheimer's Disease and Cognitive Decline
- Admin Suppl - Novel therapeutics in Parkinson's disease: Identification of alpha-synuclein binding peptides by screening
- Manipulation of polyglutamine-protein interactions
- NINDS Administrative supplement for FDA-approved compound screens for neurodegeneration
- Genetic Epidemiolgy Of Alzheimer Disease In Twins
- Arly Genes And Kindling Development
- Early Gene And Kindling Development
- Early Genes And Kindling Development
- Early Genes And Kindling Development - Cida